CITAR

Checkpoint Inhibitors Treatment Arthritis

Dear all,

We are happy to present the 1st edition of the CITAR international newsletter.

The main purposes of this study is to compare of the efficacy and safety of early use of IL-6R blockade with tocilizumab versus glucocorticoids for the treatment of arthritis induced by cancer immunotherapy by check point inhibitors: a randomized, open, multicentre, proof of concept, superiority, controlled clinical trial

Katerina Chatzidionysiou
Coordinating Investigator

Recruitment is ongoing in CITAR clinical trial

The **CITAR trial** is working hard at including patients, we are currently at **18 patients** included and **17 patients** randomized.

The recruitment is scheduled for **24 months**, in Sweden, Norway, France and the Netherlands to reach a target of 112 patients randomized into either *tocilizumab + prednisolone a*rm or *glucocorticoids arm (prednisolone)* for the treatment of arthritis induced by cancer immunotherapy

Our administrative teams are hard at work maintaining quality support system on **13** centres across Europe!

Who is the sponsor of CITAR?
CTAR is sponsored by the Karolinska University Hospital, Rheumatology Unit

Global UPDATE on Inclusions and Randomisations

Congratulations for the 1st patient randomized in a French centre! (Rheumatology Department, Université Paris-Sud-CEA-INSERM U1184, Immunology of Viral Infections and Autoimmune Diseases, Hôpitaux Universitaires Paris-Sud-Assistance Publique-Hôpitaux de Paris (AP-HP)

Ongoing application in order to get approval for

- Uppsala University, Sweden
- Örebro University, Sweden
- Lund University, Sweden
- AMC, the Netherlands
- Oslo, Norway

The Study Design



Primary objective of the study: Does early treatment with tocilizumab have superior efficacy for controlling ICI-induced inflammatory arthritis (arm B) compared to corticosteroids alone (arm A), as assessed by the Clinical Disease Activity Index (CDAI) achieving low disease activity or remission at 16 weeks?

Primary Endpoint: % of patients in group A and group B with a Clinical Disease Activity Index (CDAI) ≤10 at week 16.

Recruitment Tips

Close collaboration with oncology, reminders to refer patients with suspected ir-arthritis before GCs start!

Useful everyday tips:

Key Contacts

Coordinating Investigator	Dr. Katerina Chatzidionysiou	Aikaterini.Chatzidionysiou@ki.se 0046 762119018
National Investigator France	Dr. Samuel Bitoun	samuel.bitoun@aphp.fr
National Investigator Netherlands		
National Investigator Norway		
National Investigator Sweden	Dr. Katerina Chatzidionysiou	Aikaterini.Chatzidionysiou@ki.se
CRO Sweden	Filip Solonowicz	filip.solonowicz@regionstockholm.se